JP7532511B2 - Ｊａｋ阻害剤による尋常性白斑の局所治療 - Google Patents

Ｊａｋ阻害剤による尋常性白斑の局所治療 Download PDF

Info

Publication number
JP7532511B2
JP7532511B2 JP2022521405A JP2022521405A JP7532511B2 JP 7532511 B2 JP7532511 B2 JP 7532511B2 JP 2022521405 A JP2022521405 A JP 2022521405A JP 2022521405 A JP2022521405 A JP 2022521405A JP 7532511 B2 JP7532511 B2 JP 7532511B2
Authority
JP
Japan
Prior art keywords
week
patient
vitiligo
ruxolitinib
cream
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022521405A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545568A5 (https=
JP2022545568A (ja
Inventor
バトラー，キャスリーン
リー，ジム
スン，カン
クオ，フィオナ
ハウエル，マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=73651112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7532511(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of JP2022545568A publication Critical patent/JP2022545568A/ja
Publication of JP2022545568A5 publication Critical patent/JP2022545568A5/ja
Priority to JP2024075642A priority Critical patent/JP2024105436A/ja
Application granted granted Critical
Publication of JP7532511B2 publication Critical patent/JP7532511B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022521405A 2019-06-10 2020-06-10 Ｊａｋ阻害剤による尋常性白斑の局所治療 Active JP7532511B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024075642A JP2024105436A (ja) 2019-06-10 2024-05-08 Ｊａｋ阻害剤による尋常性白斑の局所治療

Applications Claiming Priority (25)

Application Number Priority Date Filing Date Title
US201962859584P 2019-06-10 2019-06-10
US201962859506P 2019-06-10 2019-06-10
US201962859601P 2019-06-10 2019-06-10
US201962859495P 2019-06-10 2019-06-10
US201962859532P 2019-06-10 2019-06-10
US62/859,532 2019-06-10
US62/859,495 2019-06-10
US62/859,584 2019-06-10
US62/859,506 2019-06-10
US62/859,601 2019-06-10
US201962894514P 2019-08-30 2019-08-30
US201962894541P 2019-08-30 2019-08-30
US201962894564P 2019-08-30 2019-08-30
US201962894581P 2019-08-30 2019-08-30
US201962894496P 2019-08-30 2019-08-30
US62/894,581 2019-08-30
US62/894,496 2019-08-30
US62/894,514 2019-08-30
US62/894,541 2019-08-30
US62/894,564 2019-08-30
US201962911845P 2019-10-07 2019-10-07
US62/911,845 2019-10-07
US202062967879P 2020-01-30 2020-01-30
US62/967,879 2020-01-30
PCT/US2020/036985 WO2020252012A1 (en) 2019-06-10 2020-06-10 Topical treatment of vitiligo by a jak inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024075642A Division JP2024105436A (ja) 2019-06-10 2024-05-08 Ｊａｋ阻害剤による尋常性白斑の局所治療

Publications (3)

Publication Number Publication Date
JP2022545568A JP2022545568A (ja) 2022-10-27
JP2022545568A5 JP2022545568A5 (https=) 2023-06-20
JP7532511B2 true JP7532511B2 (ja) 2024-08-13

Family

ID=73651112

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022521405A Active JP7532511B2 (ja) 2019-06-10 2020-06-10 Ｊａｋ阻害剤による尋常性白斑の局所治療
JP2024075642A Pending JP2024105436A (ja) 2019-06-10 2024-05-08 Ｊａｋ阻害剤による尋常性白斑の局所治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024075642A Pending JP2024105436A (ja) 2019-06-10 2024-05-08 Ｊａｋ阻害剤による尋常性白斑の局所治療

Country Status (9)

Country Link
US (4) US20200405627A1 (https=)
EP (1) EP3982971A4 (https=)
JP (2) JP7532511B2 (https=)
AU (2) AU2020290995B2 (https=)
CA (1) CA3150975A1 (https=)
IL (1) IL290637A (https=)
MA (1) MA56215A (https=)
TW (1) TW202112377A (https=)
WO (1) WO2020252012A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102821964B1 (ko) 2017-11-03 2025-06-19 어클라리스 쎄라퓨틱스, 인코포레이티드 치환된 피롤로피리미딘 jak 억제제 및 이의 제조 및 사용 방법
CN119080779A (zh) 2018-08-10 2024-12-06 阿克拉瑞斯治疗股份有限公司 吡咯并嘧啶itk抑制剂
JP7532511B2 (ja) 2019-06-10 2024-08-13 インサイト・コーポレイション Ｊａｋ阻害剤による尋常性白斑の局所治療
WO2022061351A1 (en) * 2020-09-16 2022-03-24 Incyte Corporation Topical treatment of vitiligo
TW202302104A (zh) * 2021-02-18 2023-01-16 美商阿克拉里斯醫療股份有限公司 Jak 1/3抑制劑的局部配方及其用於治療異位性皮膚炎和其他皮膚狀況之用法
CN117279915A (zh) * 2021-02-18 2023-12-22 阿克拉瑞斯治疗股份有限公司 Jak1/3抑制剂的局部制剂及其用于特异性皮炎和其他皮肤病况的治疗的方法
EP4389114A4 (en) * 2021-08-19 2025-09-03 Zhuhai United Laboratories Co Ltd LOCAL TOPICAL FORMULATION CONTAINING A JAK INHIBITOR OR A SALT THEREOF OR A CRYSTALLINE FORM THEREOF, PREPARATION METHOD THEREOF AND CORRESPONDING APPLICATION
CN115869321A (zh) 2021-09-28 2023-03-31 杭州中美华东制药有限公司 一种芦可替尼组合物及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080312259A1 (en) 2007-06-13 2008-12-18 Incyte Corporation SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE
US20150250790A1 (en) 2010-05-21 2015-09-10 Incyte Corporation Topical formulation for a jak inhibitor
WO2018200786A1 (en) 2017-04-26 2018-11-01 Yale University Compositions and methods for treating vitiligo
US20190060311A1 (en) 2017-08-24 2019-02-28 Aclaris Therapeutics, Inc. Compositions and methods for treatment of vitiligo
US20190125750A1 (en) 2005-12-13 2019-05-02 Incyte Corporation HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
PT1107964E (pt) 1998-08-11 2010-06-11 Novartis Ag Derivados de isoquinolina com actividade inibidora da angiogénese
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
BR0212760A (pt) 2001-09-19 2004-12-07 Aventis Pharma Sa Compostos quìmicos
DE60213842T2 (de) 2001-10-30 2007-09-06 Novartis Ag Staurosporin-derivate als hemmer der flt3-rezeptor-tyrosinkinase-wirkung
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
EP1542768A1 (en) 2002-09-20 2005-06-22 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
AU2005309019A1 (en) 2004-11-24 2006-06-01 Novartis Ag Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors
AU2017358703A1 (en) 2016-11-10 2019-05-09 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases
MA52655A (fr) 2018-03-30 2021-02-17 Incyte Corp Biomarqueurs pour maladie cutanée inflammatoire
CN111374639A (zh) 2018-12-28 2020-07-07 陈柏龄 败血症的菌种预测系统与方法
US20210030672A1 (en) 2019-06-10 2021-02-04 Incyte Corporation Topical treatment of vitiligo by a jak inhibitor
JP7532511B2 (ja) * 2019-06-10 2024-08-13 インサイト・コーポレイション Ｊａｋ阻害剤による尋常性白斑の局所治療

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190125750A1 (en) 2005-12-13 2019-05-02 Incyte Corporation HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
US20080312259A1 (en) 2007-06-13 2008-12-18 Incyte Corporation SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE
US20150250790A1 (en) 2010-05-21 2015-09-10 Incyte Corporation Topical formulation for a jak inhibitor
WO2018200786A1 (en) 2017-04-26 2018-11-01 Yale University Compositions and methods for treating vitiligo
US20190060311A1 (en) 2017-08-24 2019-02-28 Aclaris Therapeutics, Inc. Compositions and methods for treatment of vitiligo

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib，J AM ACAD DERMATOL，2017年，vol.76, no.6，pp.1054-1060，DOI:10.1016/J.JAAD.2017.02.049
Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narow-band ultraviolet B，J AM ACAD DERMATOL，2018年，vol.78, no.6，pp.1205-1207,1207.e1

Also Published As

Publication number Publication date
AU2026200410A1 (en) 2026-02-12
MA56215A (fr) 2022-04-20
US20230355628A1 (en) 2023-11-09
US20200383986A1 (en) 2020-12-10
US20220409622A1 (en) 2022-12-29
WO2020252012A1 (en) 2020-12-17
AU2020290995B2 (en) 2025-12-11
AU2020290995A1 (en) 2022-04-07
US11590138B2 (en) 2023-02-28
TW202112377A (zh) 2021-04-01
JP2024105436A (ja) 2024-08-06
US11602536B2 (en) 2023-03-14
US12233067B2 (en) 2025-02-25
EP3982971A1 (en) 2022-04-20
EP3982971A4 (en) 2023-08-16
IL290637A (en) 2022-04-01
US20200405627A1 (en) 2020-12-31
CA3150975A1 (en) 2020-12-17
JP2022545568A (ja) 2022-10-27

Similar Documents

Publication Publication Date Title
JP7532511B2 (ja) Ｊａｋ阻害剤による尋常性白斑の局所治療
US20210030672A1 (en) Topical treatment of vitiligo by a jak inhibitor
US12396993B2 (en) Ruxolitinib formulation for reduction of itch in atopic dermatitis
US20220265572A1 (en) Remittive effects of tapinarof in the treatment of plaque psoriasis, atopic dermatitis, or radiation dermatitis
AU2024204716A1 (en) Treatment of alopecia areata
US20220395472A1 (en) Remittive effects of tapinarof in the treatment of plaque psoriasis, atopic dermatitis, or radiation dermatitis
US20250275974A1 (en) Treatment of frontal fibrosing alopecia
US20230293431A1 (en) Topical treatment of vitiligo by a jak inhibitor
EA052074B1 (ru) Топическое лечение витилиго ингибитором jak

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230612

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20230728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230816

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240508

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240527

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240702

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240731

R150 Certificate of patent or registration of utility model

Ref document number: 7532511

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150